Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers

-- Selective and complete eradication of leukemic cells with an ADC targeting the pan-blood marker CD45 -- -- Engineered hematopoietic Stem Cells (HSCs) shielded from the CD45-targeting ADC maintain

Related Keywords

Switzerland ,Steve Edelson ,Lukas Jeker ,Stefanie Urlinger ,University Of Basel ,Cimeio Therapeutics Inc ,Basel University Hospital ,Stem Cells ,Chief Scientific Officer ,Cimeio Therapeutics ,Ihr Portfolio ,